Searched for: person:friedd03
in-biosketch:yes
Treatment of cytomegalovirus retinitis with intraocular sustained-release ganciclovir implant [Comment]
Friedberg DN
PMID: 7487584
ISSN: 0003-9950
CID: 14733
Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. Syntex Cooperative Oral Ganciclovir Study Group [see comments] [Comment]
Drew WL; Ives D; Lalezari JP; Crumpacker C; Follansbee SE; Spector SA; Benson CA; Friedberg DN; Hubbard L; Stempien MJ; et al
BACKGROUND. Cytomegalovirus retinitis, a sight-threatening infection associated with the acquired immunodeficiency syndrome (AIDS), currently requires lifelong intravenous treatment. An effective oral treatment would be an important advance. METHODS. We compared oral with intravenous ganciclovir in an open-label, randomized study in patients with AIDS and newly diagnosed, stable cytomegalovirus retinitis (the disease was stabilized by three weeks of treatment with intravenous ganciclovir). Sixty subjects were randomly assigned to maintenance therapy with intravenous ganciclovir at a dose of 5 mg per kilogram of body weight daily, and 63 to maintenance therapy with oral ganciclovir at a dose of 3000 mg daily. The subjects were followed for up to 20 weeks, with photography of the fundi conducted every other week. The photographs were evaluated at the completion of the study by an experienced grader who was unaware of the subjects' treatment assignments. RESULTS. Efficacy could be evaluated in 117 subjects; photographs were ungradable for 2 of the 117. On the basis of the masked assessment of photographs from 115 subjects, the mean time to the progression of retinitis was 62 days in those given intravenous ganciclovir and 57 days in those given oral ganciclovir (P = 0.63; relative risk [oral vs. intravenous], 1.08; 95 percent confidence interval for the difference in means, -22 to +12 days). On the basis of funduscopy by ophthalmologists who were aware of the subjects' treatment assignments, the mean time to progression was 96 days in subjects given intravenous ganciclovir and 68 days in subjects given oral ganciclovir (P = 0.03; relative risk [oral vs. intravenous], 1.68; 95 percent confidence interval for the difference in means, -45 to -11 days). Survival, changes in visual acuity, the incidence of viral shedding, and the incidence of adverse gastrointestinal events were similar in the two groups. Neutropenia, anemia, intravenous-catheter-related adverse events, and sepsis were more common in the group given intravenous ganciclovir. CONCLUSIONS. Oral ganciclovir is safe and effective as maintenance therapy for cytomegalovirus retinitis and is more convenient for patients to take than intravenous ganciclovir
PMID: 7637721
ISSN: 0028-4793
CID: 14734
ANTIVIRAL EFFECTS OF FOSCARNET AND GANCICLOVIR THERAPY ON HUMAN-IMMUNODEFICIENCY-VIRUS P24 ANTIGEN IN PATIENTS WITH AIDS AND CYTOMEGALOVIRUS RETINITIS
QUINN, TC; JABS, DA; HOLBROOK, JT; HARDY, WD; POLSKY, B; LEWIS, RA; CLOGSTON, P; FAINSTEIN, V; GROSS, R; SAMO, T; TUTTLE, C; APUZZO, L; BARTLETT, J; DUNN, JP; ELDRED, L; FEINBERG, J; FLYNN, T; KING, R; BARRON, B; GREENSPAN, D; LECOUNT, C; PEYMAN, G; FRANKLIN, R; HEINEMANN, M; SQUIRES, K; WISECAMPBELL, S; FRIEDMAN, AH; CHEUNG, TW; JUSTIN, N; TEICH, SA; SACKS, H; SEVERIN, C; FRIEDBERG, DN; ADDESSI, A; DIETERICH, D; LAFLEUR, F; WEINBERG, D; JAMPOL, L; MURPHY, R; NAUGHTON, K; HENDERLY, D; HOLLAND, GN; CHAFEY, S; FALL, H; KIMBRELL, C; MACARTHUR, LJ; FREEMAN, WR; MEIXNERT, L; PETERSON, TJ; QUICENO, JI; RICKMAN, L; SIMANELLO, MA; SPECTOR, S; ODONNELL, J; HOFFMAN, J; IRVINE, A; JACOBSON, M; LARSON, J; SEIFF, S; WARNER, L; DAVIS, J; CHUANG, E; ESPINAL, M; MENDEZ, P; CHEESEMAN, SH; GITTINGER, J; HAUBRICH, R; KACHADOORIAN, H; TOLSON, K; BROWNBELLAMY, J; KLEMM, AC; MARKOWITZ, JA; MEINERT, CL; AMENDLIBERCCI, A; COLESON, L; COLLINS, KL; COLLISON, BJ; DODGE, J; DONITHAN, M; EWING, C; FINK, N; GERCZAK, C; ISAACSON, MR; KAPLANGILIPIN, A; HUFFMAN, R; LEVINE, CR; NOWAKOWSKI, DJ; SMITH, M; TONASCIA, J; VANNATTA, ML; AGRESSEGAL, M; ARMSTRONG, J; BROTHERS, R; HUBBARD, L; HURLBURT, D; MAGLI, Y; MINER, K; THOMAS, S; VANDERHOOFYOUNG, M; STEWART, G; HUGHES, R; LEEF, J; PALMER, S; MOWERY, R; ELLENBERG, S; KORVICK, J; DAVIS, MD; CLARK, T; MERIN, L; SATTLER, F; JORDAN, C; MILLS, J; BROWN, BW; CONWAY, B; GRIZZLE, J; NUSSENBLATT, R; PHAIR, J; SMITH, H; KLINE, R; MOSS, M; CARELLA, A
To examine whether the prolonged survival seen in patients treated with foscarnet compared with those treated with ganciclovir was due to a direct effect on human immunodeficiency virus (HIV) replication, HIV p24 antigen was measured. Of 71 receiving foscarnet, 54% were p24 antigen-positive at enrollment (vs. 44% of 79 receiving ganciclovir). By immune complex-dissociated (ICD) p24 antigen analysis, 87% and 78%, respectively, were positive. After 1 month of treatment, there was a significant decline in standard (mean decline, 10.1 pg/mL) and ICD (mean, 39.6 pg/mL) p24 antigen in both groups (P = .0001). Mortality was greater in those who were ICD p24 antigen-positive than in those -negative at baseline (P = .03) and in subjects with an increase in ICD p24 antigen than in those with a decline (P = .09). Thus, each drug had a suppressive effect on circulating p24 antigen, which was predictive of improved survival. The inhibitory effect on CMV replication may have a beneficial effect on limiting HIV replication
ISI:A1995RR07300001
ISSN: 0022-1899
CID: 86764
INTRAOCULAR PRESSURES IN HIV-INFECTED PATIENTS [Meeting Abstract]
LORENZOLATKANY, M; LATKANY, P; FRIEDBERG, DN
ISI:A1995QM91501474
ISSN: 0146-0404
CID: 87334
LABORATORY DIAGNOSIS OF MICROSPORIDIAL KERATITIS [Meeting Abstract]
STENSON, SM; DIDIER, ES; FRIEDBERG, DN
ISI:A1995QM91501472
ISSN: 0146-0404
CID: 87333
MORBIDITY AND TOXIC EFFECTS ASSOCIATED WITH GANCICLOVIR OR FOSCARNET THERAPY IN A RANDOMIZED CYTOMEGALOVIRUS RETINITIS TRIAL
LEWIS, RA; CLOGSTON, P; FAINSTEIN, V; GROSS, R; SAMO, T; TUTTLE, C; JABS, DA; APUZZO, L; BARTLETT, J; COLESON, L; DUNN, JP; ELDRED, L; FEINBERG, J; FLYNN, T; KING, R; LESLIE, J; BARRON, B; GREENSPAN, D; LECOUNT, C; PEYMAN, G; FRANKLIN, R; HEINEMANN, MH; POLSKY, B; SQUIRES, K; WISECAMPBELL, S; FRIEDMAN, AH; CHEUNG, TW; JUSTIN, N; TEICH, S; SACKS, H; SEVERIN, C; FRIEDBERG, DN; ADDESSI, A; DIETERICH, D; FROST, K; WEINBERG, D; JAMPOL, L; MURPHY, R; NAUGHTON, K; HENDERLY, D; HOLLAND, GN; CHAFEY, S; FALL, H; HARDY, WD; KIMBRELL, C; MACARTHUR, LJ; FREEMAN, WR; MEIXNERT, L; PETERSON, TJ; QUICENO, JI; RICKMAN, L; SIMANELLO, MA; SPECTOR, S; ODONNELL, J; HOFFMAN, J; IRVINE, A; JACOBSON, M; LARSON, J; SEIFF, S; WANNER, M; DAVIS, J; CHUANG, E; ESPINAL, M; MENDEZ, P; VANDENBROUCKE, R; CHEESEMAN, SH; GITTINGER, J; HAUBRICH, R; KACHADOORIAN, H; TOLSON, K; KLINE, JM; KLEMM, AC; STEVENS, M; WEBB, R; BROWNBELLAMY, J; MARKOWITZ, JA; MEINERT, CL; BINDER, KL; BROOKMEYER, R; BROWN, VE; COLLISON, BJ; DODGE, J; DONITHAN, M; FINK, N; GERCZAK, C; HOLBROOK, JT; ISAACSON, MR; JONES, CP; LEVINE, CR; MIN, YI; MEINERT, JL; OWENS, RM; NOWAKOWSKI, DJ; SAAH, A; SANDFORD, GR; SINGER, S; SMITH, M; STERNBERG, AL; TONASCIA, J; VANNATTA, ML; DAVID, MD; AGRESSEGAL, M; ARMSTRONG, J; BROTHERS, R; FREITAG, G; HUBBARD, L; HURLBURT, D; KASTORFF, L; MAGLI, Y; MINER, K; THOMAS, S; VANDERHOOFYOUNG, M; STEWART, G; HUGHES, R; WELCH, L; MOWERY, R; ELLENBERG, S; KORVICK, J; DAVIS, MD; CLARK, T; CLOGSTON, PS; FREEMAN, W; SATTLER, F; JORDAN, C; MILLS, J; BROWN, BW; CONWAY, B; GRIZZLE, J; NUSSENBLATT, R; PHAIR, J; SMITH, H
Background: The Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial compared the use of either ganciclovir or foscarnet for the initial treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. We previously reported that patients treated with foscarnet lived longer but were more likely to have their treatment switched, the latter suggesting foscarnet may not have been as well tolerated as ganciclovir. This study compared the morbidity and toxic reactions reported during the trial. Methods: Two hundred thirty-four patients with the acquired immunodeficiency syndrome and preciously untreated cytomegalovirus retinitis at 11 university centers were randomly assigned to receive intravenously either foscarnet (n = 107) or ganciclovir (n = 127). Medical histories, laboratory tests, and drug treatment histories during the first 6 months of treatment were analyzed. Results: Neutropenia was more common in patients assigned to ganciclovir than to foscarnet (34% vs 14%; P = .001). Patients assigned to foscarnet reported more infusion-related symptoms (58% vs 24%; P < .001) and, in male patients, more genitourinary symptoms (36% vs 16%; P > .001); they also experienced a trend toward more nephrotoxic effects (13% vs 6%; P = .082) and electrolyte abnormalities. The incidence of seizures was similar in both groups (foscarnet, 12%; ganciclovir, 9%; P = .511). Patients assigned to foscarnet were more likely to be switched to the alternative treatment (foscarnet to ganciclovir, 46%; ganciclovir to foscarnet, 11%, P < .001), and most of this excess was attributable to toxic reactions. In 88% of cases in which treatment was snitched as a result of toxic reactions and in which follow-up data were available, the toxic reaction resolved after the switch. No permanent disability or death resulted from toxic reactions. Conclusions: Compared with ganciclovir, the use of foscarnet was more frequently limited by the occurrence of toxic reactions. However, these toxic reactions rarely had long-term sequelae. In light of the previously reported survival benefit seen in patients treated with foscarnet, these data support the use of foscarnet for the initial treatment of cytomegalovirus retinitis
ISI:A1995QA05800008
ISSN: 0003-9926
CID: 87463
AIDS and the eye
Friedberg, Dorothy Nahm; Stenson, Susan M
New Orleans, LA : Contact Lens Association of Ophthalmologists, c1995
Extent: 154 p. : ill. (some col.) ; 26 cm
ISBN: n/a
CID: 503
PHASE-II DOSE-RANGING TRIAL OF FOSCARNET SALVAGE THERAPY FOR CYTOMEGALOVIRUS RETINITIS IN AIDS PATIENTS INTOLERANT OF OR RESISTANT TO GANCICLOVIR (ACTG PROTOCOL 093)
JACOBSON, MA; WULFSOHN, M; FEINBERG, JE; DAVIS, R; POWER, M; OWENS, S; CAUSEY, D; HEATHCHIOZZI, ME; MURPHY, RL; CHEUNG, TW; DIETERICH, DT; SPECTOR, SA; MCKINLEY, GF; PARENTI, DM; CRUMPACKER, C; NISHIMOTO, B; LEEDOM, JM; KRAMER, F; COHEN, C; LOFTUS, J; KESSLER, HA; POTTAGE, JC; BENSON, CA; PHAIR, JP; GERITS, P; CHUSID, E; SACKS, HS; FRIEDBERG, D; CURRANKRIKORIAN, K; VALENTINE, FT; MENG, TC; FREEMAN, WR; MEIXNER, L; RICHMAN, D; ODONNELL, JJ; KIMBRELL, C; BOGGIO, K; LARSON, J; WHITMORE, PV; SIMON, GL; LELACHEUR, S; FIFE, K; ZWICKL, B; RELUE, J; STEIGBIGEL, RT; FUHRER, J; DONLON, W; BURK, RA; PORTMORE, AC; WEISSBACH, NE; HOOTON, TM; HOLZWORTH, P; DAVISON, S; COLLIER, AC; POWDERLY, WG; KLEBERT, M; ROYAL, M; SEYFRIED, W; SQUIRES, KC; WEISS, W; BARBACCI, M; BECKER, RL; JABS, D; BARTLETT, JG; PARA, MF; JONES, M; NEIDIG, JL; FASS, RJ; VANDERHORST, C; KYLSTRA, J; RAASCH, R; BLOODGOOD, K; WOLITZ, R; KIRK, S; ROLFE, L; PATRONEREESE, J; BARTLETT, JA; WASKIN, HA; WILLIAMS, DK; SHIP, KW; KAHL, P; ASSAYKEEN, T; KAROL, C; MARTINMUNLEY, S; SUMNER, P
Objective: To document response to foscarnet salvage therapy in patients with cytomegalovirus (CMV) retinitis who are intolerant of or resistant to ganciclovir. Methods: Patients with AIDS and CMV retinitis who had documented hematologic intolerance or resistance to ganciclovir therapy received an induction course of foscarnet, 60 mg/kg every 8h for 14 days, and subsequent chronic maintenance foscarnet therapy at a daily dose of 60, 90 or 120 mg/kg/day. The first 87 patients were randomly assigned to receive maintenance foscarnet at a dose of 60 or 90 mg/kg/day; all subsequent patients were assigned a maintenance dose of 120 mg/kg/day. Results: A total of 156 evaluable patients were enrolled. Median time to retinitis progression and survival did not differ significantly among groups assigned to different maintenance foscarnet doses. Among patients with retinitis progression documented ophthalmologically occuring at less-than-or-equal-to 2 week intervals, despite optimal doses of ganciclovir, time to progression on foscarnet therapy was a median 8 weeks at all doses studied. By dose assignment, there were no significant differences in serious drug-associated toxicity, although trends toward increased renal and hypocalcemic adverse events were observed at higher maintenance doses. Conclusion: in patients intolerant of ganciclovir, salvage foscarnet therapy resulted in a longer time to retinitis progression than reported previously in historic controls who terminated ganciclovir therapy. In patients who exhibited clinical resistance to ganciclovir, foscarnet appeared to have efficacy in controlling retinitis. No significant differences in either efficacy or toxicity were observed in the range of foscarnet maintenance doses studied
ISI:A1994NC29800006
ISSN: 0269-9370
CID: 52528
HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) ASSOCIATED UVEITIS [Meeting Abstract]
HEINEMANN, MH; ROSBERGER, DF; FRIEDBERG, DN; HOLLAND, GN
ISI:A1994MZ58500245
ISSN: 0146-0404
CID: 52540
Risk factors for development of rhegmatogenous retinal detachment in patients with cytomegalovirus retinitis [see comments] [Comment]
Freeman WR; Friedberg DN; Berry C; Quiceno JI; Behette M; Fullerton SC; Munguia D
We studied 259 patients to determine the time-dependent risk and risk factors for the development of retinal detachment in patients with cytomegalovirus retinitis. The six-month and one-year retinal detachment rates (by eye) were 11% and 24%, respectively. Increasing retinal surface involvement outside of the posterior pole and the presence of retinitis activity were found to be the two covariates that best predicted retinal detachment. Eyes with peripheral involvement greater than 25% had a fivefold risk for detachment, compared to eyes with 10% involvement. If there was retinitis activity and more than 25% peripheral (external to major vascular arcades) involvement, the risk increased to 24-fold. The presence of a fellow eye with retinal detachment was not an independent risk factor. These observations should help in the design of a prophylactic trial intended to prevent retinal detachment and should also help ophthalmologists counsel patients with cytomegalovirus retinitis
PMID: 8250074
ISSN: 0002-9394
CID: 14735